ANIP ACQUISITION COMPANY TRANSACTION BONUS AGREEMENTTransaction Bonus Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
THIS TRANSACTION BONUS AGREEMENT (“Agreement”) is entered into this 22nd day of September, 2012 (the “Effective Date”), by and between ANIP Acquisition Company (the “Company”) and Arthur Przybyl (the “Executive”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Georgia
THIS LOAN AND SECURITY AGREEMENT (together with all schedules, riders and exhibits annexed hereto from time to time, this “Agreement”) is entered into this 6th day of June, 2012, between ALOSTAR BANK OF COMMERCE, a state banking institution incorporated or otherwise organized under the laws of the State of Alabama (“Lender”), and ANIP ACQUISITION COMPANY, a Delaware corporation (“Borrower”). All schedules, riders and exhibits annexed hereto are incorporated herein and made a part hereof.
Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***]...Master Product Development and Collaboration Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This MASTER PRODUCT DEVELOPMENT AND COLLABORATION AGREEMENT is made as of the 11th day of July 2011, by and among ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“ANI”), having a place of business at 210 Main Street West, Baudette, MN 56623 and RiconPharma LLC, a limited liability company having its principal office at 100 Ford Road, Suite #9, Denville, NJ 07834 (“RiconPharma”). ANI and RiconPharma may each be referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***]...Generic Wholesale Service Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Ohio
Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***]...Supplier Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
This SUPPLIER AGREEMENT (“Agreement”) is made as of this 1st day of November, 2010, by and between McKesson Corporation (“McKesson”) and ANIP Acquisition Company (“Supplier” and together with McKesson, the “Parties” and individually, each a “Party”).
Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***]...Sublicense Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Sublicense Agreement (the “Agreement”) is entered into as of the 30th day of October, 2009 by and between ANIP ACQUISITION COMPANY, d/b/a ANI PHARMACEUTICALS, INC., a Delaware corporation (“ANI”), and JAZZ PHARMACEUTICALS, INC., a Delaware corporation (“Jazz Pharmaceuticals”).
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this “Amendment”) is entered into as of November 13, 2012 by and between BioSante Pharmaceuticals, Inc., a Delaware corporation and ANIP Acquisition Company (d/b/a/ ANI Pharmaceuticals), a Delaware corporation.
NOTE PURCHASE AGREEMENTNote Purchase Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
This NOTE PURCHASE AGREEMENT (this “Agreement”) dated as of January 28, 2011, is by and among ANIP ACQUISITION COMPANY, a Delaware corporation doing business as ANI Pharmaceuticals, Inc. (the “Company”) and MERIDIAN VENTURE PARTNERS II, L.P., a Delaware limited partnership (“MVP II” or the “Agent”) and the other parties executing signature pages hereto or who become a party hereto pursuant to the provisions of Sections 1.3(a)(iii) or 1.3(c)(iii) below (collectively with the Agent, the “Lenders”).
ANIP ACQUISITION COMPANY As of October 3, 2012Fee Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
ANIP ACQUISITION COMPANY As of October 3, 2012Management Fee Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
EMPLOYMENT AGREEMENTEmployment Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This Employment Agreement (the “Agreement”) by and between ANIP Acquisition Company, a Delaware corporation (the “Company” and for purposes of Sections 3, 5, 6, 8 and 14 hereof, the term “Company” shall be deemed to include all subsidiaries of the Company), and James Marken (“Employee”) is hereby entered into and effective as of May 1, 2007
Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***]...Manufacturing Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***]...Development, Manufacturing and Supply Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Wisconsin
This DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT (“this Agreement”), dated as of February 5, 2009 (the “Effective Date”), is by and between ANI PHARMACEUTICALS, INC., a Delaware Corporation (“ANI”), and COUNTY LINE PHARMACEUTICALS, LLC., a Wisconsin Limited Liability Corporation (“CLP”).
Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***]...Manufacturing Transfer and Supply Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Wisconsin
This MANUFACTURING TRANSFER AND SUPPLY AGREEMENT (“this Agreement”), dated as of March 31, 2010 (the “Effective Date”), is by and between ANIP ACQUISITION COMPANY d/b/a ANI PHARMACEUTICALS, INC., a Delaware corporation (“ANI”), and COUNTY LINE PHARMACEUTICALS, LLC., a Wisconsin limited liability company (“CLP”).
